 Connie Hess
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 39 | 2023 | 380 | 11.670 |
Why?
| | Percutaneous Coronary Intervention | 22 | 2021 | 445 | 4.810 |
Why?
| | Coronary Artery Disease | 15 | 2020 | 607 | 4.550 |
Why?
| | Myocardial Infarction | 18 | 2023 | 931 | 4.240 |
Why?
| | Lower Extremity | 18 | 2023 | 337 | 4.160 |
Why?
| | Platelet Aggregation Inhibitors | 24 | 2023 | 399 | 3.610 |
Why?
| | Fibrinolytic Agents | 9 | 2022 | 233 | 3.110 |
Why?
| | Endovascular Procedures | 7 | 2023 | 269 | 3.060 |
Why?
| | Radial Artery | 9 | 2019 | 64 | 2.780 |
Why?
| | Purinergic P2Y Receptor Antagonists | 8 | 2018 | 62 | 2.530 |
Why?
| | Acute Coronary Syndrome | 7 | 2023 | 254 | 2.380 |
Why?
| | Vascular Surgical Procedures | 6 | 2021 | 262 | 2.210 |
Why?
| | Rivaroxaban | 12 | 2023 | 211 | 2.030 |
Why?
| | Aspirin | 13 | 2023 | 326 | 2.030 |
Why?
| | Ischemia | 9 | 2023 | 363 | 1.860 |
Why?
| | Stroke | 10 | 2022 | 1017 | 1.660 |
Why?
| | Femoral Artery | 8 | 2023 | 168 | 1.590 |
Why?
| | Treatment Outcome | 40 | 2023 | 9162 | 1.570 |
Why?
| | Anticoagulants | 9 | 2023 | 549 | 1.530 |
Why?
| | Hemorrhage | 15 | 2023 | 618 | 1.490 |
Why?
| | Postoperative Complications | 6 | 2021 | 2164 | 1.480 |
Why?
| | Drug-Eluting Stents | 4 | 2021 | 62 | 1.450 |
Why?
| | Anticholesteremic Agents | 3 | 2023 | 129 | 1.390 |
Why?
| | Hypercholesterolemia | 2 | 2022 | 92 | 1.340 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 234 | 1.320 |
Why?
| | Atherosclerosis | 5 | 2023 | 342 | 1.320 |
Why?
| | Patient Readmission | 4 | 2021 | 609 | 1.290 |
Why?
| | Atrial Fibrillation | 4 | 2017 | 325 | 1.140 |
Why?
| | Cardiovascular Diseases | 6 | 2023 | 1729 | 1.140 |
Why?
| | Aged | 40 | 2022 | 19294 | 1.100 |
Why?
| | Disease Management | 4 | 2021 | 563 | 1.070 |
Why?
| | Ticlopidine | 3 | 2016 | 55 | 1.040 |
Why?
| | Humans | 87 | 2023 | 115741 | 1.030 |
Why?
| | Saphenous Vein | 2 | 2015 | 31 | 0.970 |
Why?
| | Graft Occlusion, Vascular | 2 | 2015 | 35 | 0.970 |
Why?
| | Factor Xa Inhibitors | 6 | 2021 | 138 | 0.930 |
Why?
| | Learning Curve | 2 | 2015 | 63 | 0.920 |
Why?
| | Cardiac Catheterization | 3 | 2018 | 538 | 0.910 |
Why?
| | Female | 51 | 2023 | 60018 | 0.900 |
Why?
| | Coronary Artery Bypass | 2 | 2015 | 196 | 0.890 |
Why?
| | Thrombosis | 3 | 2022 | 302 | 0.880 |
Why?
| | Pyridones | 2 | 2015 | 125 | 0.880 |
Why?
| | Middle Aged | 35 | 2023 | 27069 | 0.870 |
Why?
| | Warfarin | 2 | 2015 | 136 | 0.870 |
Why?
| | Risk Factors | 23 | 2023 | 8702 | 0.860 |
Why?
| | Male | 45 | 2023 | 56050 | 0.860 |
Why?
| | Sex Characteristics | 3 | 2023 | 641 | 0.860 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 81 | 0.840 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 373 | 0.840 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 50 | 0.830 |
Why?
| | Postoperative Hemorrhage | 2 | 2013 | 78 | 0.830 |
Why?
| | Brain Ischemia | 2 | 2022 | 298 | 0.800 |
Why?
| | Coronary Vessels | 3 | 2023 | 230 | 0.780 |
Why?
| | Paclitaxel | 2 | 2021 | 192 | 0.770 |
Why?
| | Pyrazoles | 2 | 2015 | 362 | 0.770 |
Why?
| | Diabetes Complications | 2 | 2021 | 212 | 0.760 |
Why?
| | Heparin | 3 | 2023 | 227 | 0.750 |
Why?
| | Gout | 2 | 2018 | 37 | 0.750 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 196 | 0.740 |
Why?
| | Hypolipidemic Agents | 1 | 2021 | 87 | 0.730 |
Why?
| | Angina Pectoris | 2 | 2017 | 62 | 0.700 |
Why?
| | Dyslipidemias | 1 | 2021 | 154 | 0.680 |
Why?
| | Leg | 1 | 2021 | 227 | 0.670 |
Why?
| | Risk Assessment | 11 | 2021 | 2990 | 0.630 |
Why?
| | Myocardial Revascularization | 2 | 2016 | 67 | 0.630 |
Why?
| | Reperfusion | 1 | 2018 | 38 | 0.630 |
Why?
| | Consensus | 2 | 2017 | 537 | 0.610 |
Why?
| | Drug Therapy, Combination | 10 | 2023 | 962 | 0.590 |
Why?
| | Upper Extremity | 1 | 2018 | 84 | 0.590 |
Why?
| | Time Factors | 13 | 2021 | 6171 | 0.580 |
Why?
| | Databases, Factual | 2 | 2021 | 1139 | 0.580 |
Why?
| | Coronary Angiography | 3 | 2017 | 307 | 0.570 |
Why?
| | Registries | 10 | 2019 | 1770 | 0.560 |
Why?
| | Medicare | 4 | 2021 | 668 | 0.510 |
Why?
| | Cholesterol, LDL | 4 | 2023 | 309 | 0.510 |
Why?
| | Acute Disease | 4 | 2021 | 914 | 0.500 |
Why?
| | Quality Indicators, Health Care | 3 | 2023 | 287 | 0.490 |
Why?
| | Societies, Medical | 2 | 2023 | 684 | 0.480 |
Why?
| | Coronary Disease | 1 | 2017 | 348 | 0.470 |
Why?
| | Recurrence | 5 | 2020 | 953 | 0.470 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4442 | 0.460 |
Why?
| | Hospitals | 3 | 2017 | 585 | 0.450 |
Why?
| | United States | 20 | 2023 | 12304 | 0.450 |
Why?
| | Office Visits | 1 | 2013 | 79 | 0.430 |
Why?
| | Sex Factors | 7 | 2022 | 1739 | 0.410 |
Why?
| | Hematoma | 2 | 2022 | 50 | 0.400 |
Why?
| | Aftercare | 1 | 2013 | 187 | 0.390 |
Why?
| | Health Status Disparities | 1 | 2014 | 204 | 0.390 |
Why?
| | Subclavian Vein | 1 | 2011 | 13 | 0.380 |
Why?
| | Quality of Life | 3 | 2022 | 2388 | 0.380 |
Why?
| | Referral and Consultation | 1 | 2016 | 646 | 0.380 |
Why?
| | Subclavian Artery | 1 | 2011 | 29 | 0.370 |
Why?
| | Arteriovenous Fistula | 1 | 2011 | 29 | 0.370 |
Why?
| | Thrombocytopenia | 1 | 2012 | 175 | 0.370 |
Why?
| | Cardiology | 2 | 2023 | 260 | 0.370 |
Why?
| | Electric Countershock | 1 | 2011 | 104 | 0.360 |
Why?
| | Catheterization | 1 | 2011 | 159 | 0.350 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1088 | 0.330 |
Why?
| | Adenosine Diphosphate | 1 | 2009 | 81 | 0.330 |
Why?
| | Comorbidity | 4 | 2020 | 1473 | 0.330 |
Why?
| | Cardiovascular Agents | 2 | 2022 | 125 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1218 | 0.320 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2009 | 185 | 0.320 |
Why?
| | Retrospective Studies | 8 | 2022 | 12633 | 0.320 |
Why?
| | Healthcare Disparities | 1 | 2014 | 486 | 0.310 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 175 | 0.310 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2009 | 274 | 0.310 |
Why?
| | Peptides | 1 | 2013 | 864 | 0.300 |
Why?
| | Prospective Studies | 7 | 2022 | 6276 | 0.300 |
Why?
| | Defibrillators, Implantable | 1 | 2011 | 285 | 0.300 |
Why?
| | Cardiomyopathies | 1 | 2011 | 303 | 0.290 |
Why?
| | Vascular System Injuries | 2 | 2019 | 64 | 0.290 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 102 | 0.290 |
Why?
| | Double-Blind Method | 4 | 2020 | 1660 | 0.280 |
Why?
| | Cause of Death | 3 | 2018 | 368 | 0.280 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6423 | 0.270 |
Why?
| | Intermittent Claudication | 2 | 2023 | 108 | 0.250 |
Why?
| | Neoplasms | 2 | 2017 | 2118 | 0.250 |
Why?
| | Ankle Brachial Index | 2 | 2022 | 30 | 0.250 |
Why?
| | Popliteal Artery | 3 | 2023 | 59 | 0.250 |
Why?
| | Endothelial Cells | 1 | 2009 | 696 | 0.230 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 816 | 0.230 |
Why?
| | Patient Discharge | 3 | 2021 | 770 | 0.230 |
Why?
| | Age Factors | 4 | 2016 | 2911 | 0.230 |
Why?
| | Arteries | 2 | 2022 | 250 | 0.220 |
Why?
| | Longitudinal Studies | 5 | 2018 | 2420 | 0.220 |
Why?
| | Incidence | 5 | 2021 | 2335 | 0.220 |
Why?
| | Thromboplastin | 1 | 2023 | 71 | 0.220 |
Why?
| | Myocardial Ischemia | 2 | 2015 | 237 | 0.210 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 8 | 0.200 |
Why?
| | Walking | 2 | 2022 | 425 | 0.200 |
Why?
| | Ulcer | 1 | 2021 | 28 | 0.200 |
Why?
| | Odds Ratio | 2 | 2022 | 962 | 0.190 |
Why?
| | Lactones | 1 | 2022 | 56 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 941 | 0.190 |
Why?
| | Syndrome | 1 | 2021 | 339 | 0.180 |
Why?
| | Cholesterol | 1 | 2022 | 369 | 0.180 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 90 | 0.180 |
Why?
| | Limb Salvage | 1 | 2020 | 52 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 181 | 0.180 |
Why?
| | Hospitalization | 2 | 2019 | 1765 | 0.170 |
Why?
| | Hypertension | 2 | 2022 | 1064 | 0.170 |
Why?
| | United Kingdom | 1 | 2020 | 227 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 169 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2020 | 223 | 0.160 |
Why?
| | Extremities | 1 | 2020 | 113 | 0.160 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2018 | 6 | 0.160 |
Why?
| | Aorta | 1 | 2021 | 397 | 0.160 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2018 | 20 | 0.160 |
Why?
| | Cohort Studies | 2 | 2022 | 4949 | 0.160 |
Why?
| | Pyridines | 1 | 2022 | 425 | 0.160 |
Why?
| | Exercise Therapy | 1 | 2022 | 351 | 0.150 |
Why?
| | Antithrombins | 1 | 2018 | 49 | 0.150 |
Why?
| | Stents | 3 | 2020 | 477 | 0.150 |
Why?
| | Non-ST Elevated Myocardial Infarction | 1 | 2017 | 16 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1405 | 0.150 |
Why?
| | American Heart Association | 3 | 2023 | 266 | 0.140 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 44 | 0.140 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2017 | 51 | 0.140 |
Why?
| | Intraoperative Complications | 1 | 2017 | 126 | 0.140 |
Why?
| | Mortality | 1 | 2018 | 290 | 0.140 |
Why?
| | Uric Acid | 1 | 2017 | 150 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1265 | 0.130 |
Why?
| | Blood Platelets | 1 | 2018 | 350 | 0.130 |
Why?
| | North Carolina | 1 | 2015 | 97 | 0.130 |
Why?
| | Hospital Bed Capacity | 1 | 2014 | 21 | 0.120 |
Why?
| | Hospitals, Low-Volume | 1 | 2014 | 22 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2014 | 39 | 0.120 |
Why?
| | Smoking | 1 | 2022 | 1457 | 0.120 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2014 | 5 | 0.120 |
Why?
| | Vascular Patency | 1 | 2014 | 97 | 0.120 |
Why?
| | Prosthesis Design | 2 | 2017 | 288 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 908 | 0.110 |
Why?
| | Diagnosis-Related Groups | 1 | 2013 | 27 | 0.110 |
Why?
| | Survivors | 1 | 2017 | 404 | 0.110 |
Why?
| | Professional Competence | 1 | 2014 | 86 | 0.110 |
Why?
| | Logistic Models | 1 | 2018 | 1856 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2017 | 497 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 667 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1180 | 0.110 |
Why?
| | Fee-for-Service Plans | 1 | 2013 | 79 | 0.110 |
Why?
| | Platelet Factor 4 | 1 | 2012 | 21 | 0.110 |
Why?
| | Inflammation | 1 | 2023 | 2500 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 374 | 0.100 |
Why?
| | Heart Failure | 2 | 2016 | 1964 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 3343 | 0.090 |
Why?
| | Radiography, Interventional | 1 | 2011 | 111 | 0.090 |
Why?
| | Naphthalimides | 1 | 2009 | 2 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2009 | 3 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2014 | 779 | 0.090 |
Why?
| | Heart Diseases | 1 | 2013 | 331 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 1825 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1730 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2009 | 137 | 0.080 |
Why?
| | Communication | 1 | 2014 | 750 | 0.080 |
Why?
| | Protein Isoforms | 1 | 2009 | 339 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3037 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1127 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 332 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 793 | 0.070 |
Why?
| | Clinical Competence | 1 | 2014 | 912 | 0.070 |
Why?
| | Quality Improvement | 1 | 2014 | 958 | 0.070 |
Why?
| | Cattle | 1 | 2009 | 935 | 0.070 |
Why?
| | Young Adult | 1 | 2021 | 10518 | 0.070 |
Why?
| | Cell Movement | 1 | 2009 | 867 | 0.060 |
Why?
| | Phosphorylation | 1 | 2009 | 1571 | 0.060 |
Why?
| | Autoantibodies | 1 | 2012 | 1360 | 0.060 |
Why?
| | Subtilisin | 1 | 2023 | 3 | 0.060 |
Why?
| | Prevalence | 2 | 2021 | 2269 | 0.060 |
Why?
| | Proprotein Convertases | 1 | 2023 | 14 | 0.050 |
Why?
| | Lipoprotein(a) | 1 | 2023 | 51 | 0.050 |
Why?
| | Adolescent | 1 | 2021 | 17922 | 0.050 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 61 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2098 | 0.050 |
Why?
| | Mobility Limitation | 1 | 2022 | 60 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 61 | 0.050 |
Why?
| | Coated Materials, Biocompatible | 1 | 2021 | 57 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2021 | 88 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 145 | 0.040 |
Why?
| | Adult | 1 | 2021 | 30789 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 208 | 0.040 |
Why?
| | Punctures | 1 | 2019 | 37 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 290 | 0.040 |
Why?
| | Reoperation | 1 | 2021 | 525 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2017 | 57 | 0.040 |
Why?
| | Health Care Costs | 1 | 2021 | 384 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1086 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1870 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2017 | 63 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2017 | 130 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 4541 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 501 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 241 | 0.030 |
Why?
| | Platelet Function Tests | 1 | 2015 | 24 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 654 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 734 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 14 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 1024 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1441 | 0.030 |
Why?
| | Retreatment | 1 | 2013 | 70 | 0.030 |
Why?
| | Canada | 1 | 2014 | 335 | 0.030 |
Why?
| | Patient Preference | 1 | 2014 | 171 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 778 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 5553 | 0.020 |
Why?
| | Animals | 1 | 2009 | 32104 | 0.020 |
Why?
|
|
Hess's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|